Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

OTC Allegra Filing Possibility Prepared For By Aventis – CEO

This article was originally published in The Tan Sheet

Executive Summary

Aventis recognizes and is preparing for the possibility that consumer healthcare companies might submit applications with FDA to market OTC versions of the low-sedating antihistamine Allegra
Advertisement

Related Content

FDA Rx-To-OTC Switch Petition Refusal Would Not Result In WellPoint Suit
FDA Rx-To-OTC Switch Petition Refusal Would Not Result In WellPoint Suit
FDA Rx-To-OTC Switch Petition Refusal Would Not Result In WellPoint Suit
Pfizer, Aventis Still See Wiggle Room On FDA-Mandated Switches
Pfizer, Aventis Still See Wiggle Room On FDA-Mandated Switches
Pfizer, Aventis Still See Wiggle Room On FDA-Mandated Switches
Claritin Patent Infringement Suit Brings Industry Into OTC Antihistamine Fray
Claritin Patent Infringement Suit Brings Industry Into OTC Antihistamine Fray

Topics

Advertisement
UsernamePublicRestriction

Register

PS093670

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel